65 results about "Gene list" patented technology

The invention discloses a probe and a sequence combination for simultaneous detection of various mutation types and particularly provides a kit, a method, a gene chip, a probe and a sequence combination which are high in sensitivity and specificity and used for simultaneous detection of point mutation, short segment insertion and deletion, copy number variation and fusion genes of 57 tumor driver genes listed in a detection list. The invention further discloses a sequence combination and probe associated gene chip and kit and a method for simultaneous detection of various mutation types. By detection of body fluid including blood, hydrothorax, abdominal dropsy and the like and tumor frozen tissues or paraffin sections, comprehensive tumor driver gene mutation information can be acquired, sensitivity and accuracy in tumor gene detection are improved, and accordingly clinicians can be assisted in making of individualized medication schemes to achieve best accurate treatment effects.

The invention discloses a pharmaceutical activity prediction and selection method based on genetic expressions and drug targets. The method comprises following steps: 1) obtaining target genes corresponding to drugs to be detected according to information in drug target database; obtaining genetic expression data of disease tissues of patients and corresponding compression data and obtaining important genetic lists of morbidity processes of patients by evaluating importance of genes through a systems biology method; 2) searching for whether the target genes obtained in the step 1) target the important gene lists during mobility of the patients or not through statistical analysis of in order to predict pharmaceutical activity of patients and select drugs suited to patients. The method is easily used with high efficiency and broad application scope. The prediction method can be used for selecting drugs suitable for individual patients such that a personalized treatment schme can be provided for patients.

The invention discloses a method and device for constructing a biological information database. The method comprises the steps that according to a disease list, reference abstract resources related to a disease name are acquired from a network; each reference abstract is decomposed, so that abstract information containing abstract contents is acquired; gene and mutation information in the abstract contents is extracted and classified according to a gene list and a mutation regular expression semantic database, and classified results of each type are filtered and / or noted in combination with human genome reference sequences; a related word semantic database corresponding to the disease is established, and a gene mutation score is determined according to the related word semantic database; and data obtained at previous steps is arranged, and the biological information database is established. The method and device disclosed by the invention are characterized in that a biomedicine reference database is excavated by a text excavation algorithm, and mutation information and relations related to the disease are extracted from the database, so that the biological information database especially a human disease outbreak database which is based on research fronts, has comprehensive and reliable data and can be updated rapidly can be established.

The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.

The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and / or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and / or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.

The present invention relates to a Mycoplasma hyopneumoniae vaccine strain comprising a mutation in at least one of the genes listed or as deposited with the National Measurements Institute (Australia) under accession number NM04 / 41259, which strain is temperature sensitive and attenuated, a vaccine comprising such strains and methods and uses thereof.

The present invention relates, e.g., to a minimal set of protein-coding genes which provides the information required for replication of a free-living organism in a rich bacterial culture medium, wherein (1) the gene set does not comprise the 101 genes listed in Table 2; and / or wherein (2) the gene set comprises the 381 protein-coding genes listed in Table 3 and, optionally, one of more of: a set of three genes encoding ABC transporters for phosphate import (genes MG410, MG411 and MG412; or genes MG289, MG290 and MG291); the lipoprotein-encoding gene MG185 or MG260; and / or the glycerophosphoryl diester phosphodiesterase gene MG293 or MG385.

Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37.

The invention relates to a set of isolated marker genes comprising at least one gene identified as having differential expression as between patients who are responders and non responders to an erbB receptor tyrosine kinase inhibitor; said gene set comprising one or more genes selected from at least the group consisting of the 51 genes listed herein including gene-specific oligonucleotides derived from said genes; and uses of such sets in diagnostic applications.

A method for determining pulmonary fibrosis subtype and / or prognosis in a subject having pulmonary fibrosis comprising: a. determining an expression profile by measuring the gene expression levels of a plurality of genes selected from genes listed in Table 1, 2, 3, 4 7, 8, 9, and / or 10, in a sample from the subject; and b. classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts decreased risk of post lung transplant primary graft dysfunction, and wherein a poor prognosis predicts an increased risk of post lung transplant primary graft dysfunction.

This invention provides a molecule marking method of indicating and identifying the fat quantum of the chicken abdomen with the IGFBP2 gene, which includes the following steps: designing a pair of inciting substances IGFBP2F and IGFBP2R according to the IGFBP2 gene list of chicken; making use of the inciting substances to amplify the gene groups DNA of the chick, then applying the SSCP method, doing the electrophoresis separation to the PCR production with the polypropene amide gelatin to check out one single alkali radicle differentiation location in the IGFBP2 gene3 control area; nominating the two pure type and mixing type in this location of the IGFBP2 gene of the chicken separately. This invention can accelerate the breeding process of the low fat meat chiken.

The present invention relates to extraction of human tissue kallikrein, which is a separation and purification method of gene expressed human tissue kallikrein protein, and its operation is as follows: (1). supernatant separation; (2) chromatography; 1). step gradient elution; firstly, using buffer solution with 20-30mM and pH 7-8 to balance column, then pumping the supernatant into the column; using buffer solution containing 0.1-0.2 M of NaCl to make elution, then using the buffer solution containing 0.3-0.5 M of NaCl, collecting fraction for stand-by; firstly, using NaAc with 10-20 mM and pH 5.0-6.0 to balance column, then making step gradient elution and collecting fraction; and making linear gradient elution, in eluent salt component range is 0.1M NaCl to 0.5M NaCl, collecting fraction and storing; (3). utilizing affinity chromatography to make separation and purification.

Methods and kits for diagnosing schizophrenia are disclosed. The diagnostic method comprises analyzing in a biological sample of a subject a level of A-to-I RNA editing of at least one CNS-expressed gene as set forth in Table 1, wherein an amount of the A-to-I RNA editing of the at least one gene below a predetermined level is indicative of schizophrenia in the subject.

The invention relates to a Trc promoter mutation library and application thereof, and belongs to the technical field of biology. Promoters shown in SEQ ID NO.1-41 are obtained through a large number of screening, and the range of regulating and controlling the intensity of a target gene table is wide so that a Trc promoter mutation library is established. According to the invention, the promoter library is constructed, and the opening amount type fine adjustment gene expression becomes possible; in metabolic analysis and transformation, the disturbance on the cell genotype can be realized onlyby two non-'on ', namely'off' means of gene knockout and overexpression in the past, namely, the influence of the target gene expression on phenotype and metabolic flux distribution can be analyzed and controlled by performing gradient type accurate fine adjustment on the target gene expression.

A system for characterizing intercellular communication and heterogeneity in cancer tumors, and more particularly a method for detecting sub-populations and receptor-ligand states for providing predictive information in relation to cancer and cancer treatment is disclosed. The system comprises the steps of obtaining from a NGS sequencer, single-cell RNA-seq for a plurality of cells within a tumor, correlation with a plurality of data sets from a curated gene list of receptor-ligand pairs, normalizing their transcript abundance data, assigning states (e.g. 0,1,2,3) to each curated receptor-ligand pair in each cell (e.g. depending on {L:R}={0:0, 0:1, 1:0, 1:1}), thereby forming a matrix of receptor-ligand states, extracting sub-groups from the matrix that are not invariant and applying unsupervised clustering methods to identifying sub-clusters, identifying sub-populations within the set based on pair-wise distances between individual cells and similarity of cellular transcriptomes, identifying expressed ligands and receptors across the sub-populations, cross-referencing against the curated set of receptor-ligand pairs and providing a visually display the results by a mapping module for the clinician. The method can be used to study intercellular communication to elicit the etiology of diseases, and can be used to measure the disruption of intercellular communication to diagnose similarly disrupted disease patterns across patients.

Methods for the diagnosis of leukemias, and more specifically AML, such as MLL-AF9 AML, in a subject, based on the assessment of the expression or activity of one or more of the genes listed in Tables 1 and 2 are disclosed. The use of antibodies or antigen-binding fragments thereof that bind to one or more of proteins showing preferential expression at the cell surface of AML leukemic cells for treating AML is also disclosed.

The invention discloses a traditional Chinese medicine (TCM) active ingredient forecasting method excavated on the basis of pathway modes. The traditional Chinese medicine active ingredient forecasting method includes the following steps of collecting data of compound ingredients with Chinese Academy of Sciences (CAS) registry numbers in TCM, collecting associated genes of compounds to form compound-gene associated pairs and sorting the genes according to occurrence frequency of the associated genes to form an associated gene list, setting a threshold value to screen frequent genes to form biological pathway data sets and enable each frequent gene to correspond to one biological pathway data record, excavating the pathway modes for the biological pathway data sets, grading the frequency genes, grading activity of the compounds, and setting threshold values for scores of the genes and scores of the activity of the compounds. The compound-gene associated pairs are screened according to the threshold values. The remaining compounds are reserved. Consequently, active ingredients of the TCM can be forecasted.

This invention presents a alterable gene preparation method of high neutralizations active high affinity anti-TNF-mAb(D6 mAb) mutable gene. It prepares a group little mouse anti-human single-clone antibody by regrouping human TNF immune BALB / c little mouse. From the interdiction experiment outside body, it can filtrate anti-human TNF single-clone antibody with high neutralization. From cloning this single-clone antibody heavy chains alterable gene, it gets its alterable gene and amino acid sequcence, and affirms the unique of its gene and albumen list. This invention select high neutralization D2 crossbreed cell line to clone heavy chains alterable gene successfully, and gets its special nucleotide list after testing. Coding the alterable gene list has huge potential value in forming human vector and gomphosis vector which can cure inflammation and self-immunity disease etc.

The current invention relates to new tools and methods enabling neuroblastoma patient stratification into prognostic favorable or unfavorable groups. The invention is based on the re-analysis of published gene expression data-sets studying neuroblastoma tumors generating different prognostic gene lists. The overlapping gene lists were subsequently tested for their prognostic power on both the published tumor samples and on an unseen large set of unpublished samples, greatly increasing the statistical power of prognostic analyses. In addition, expression analysis of miRNAs in neuroblastoma tumors with different prognosis was performed. By doing this, the inventors could establish a neuroblastoma prognostic classifier with highly improved prognostic power, which is independent from the tumor sample set used to establish it. This classifier and its related prognostic tools and methods are thus perfectly suitable for routine clinical assessment of neuroblastoma prognosis.

The invention discloses a source tracking system using lithologic geochemical genes, and belongs to the field of geological sample detection tracking systems. The source tracking system is characterized in that the geochemical genes represent the characteristics of the relative change trend of the content between elements of geological samples, and different geological samples have different geochemical genes, so the geochemical genes can be utilized to identify the geological samples. However, due to the complexity of the geological action, the geochemical properties of the elements may change in some special geological environments, resulting in a change trend among the elements, i.e., the geochemical genes of geological samples with the same source may change within a certain range (i.e., the variability of the genes).

The invention relates to the use of inhibitors of the expressed proteins of the murine genes and / or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds.

The invention discloses a RapMap method for rapid and high-throughput positioning and cloning of a plant QTL gene. The method comprises the steps of: selecting strains with relatively small characterdifferences from the core germplasm as gradient parents; constructing as many F2 gradient genetic populations as possible; preliminarily positioning QTL by performing chip detection or next-generationsequencing on two separated extreme phenotypic DNA pools of each group, verifying the QTL at the single plant level of each gradient group according to the co-separation criteria provided by the invention, and cloning a target gene by using a QTL heterozygous family as a near-isogenic line for fine positioning. The concept of gradient genetic populations and the idea of co-segregation criteria are the core of the invention. Six rice grain length and grain width genes are successfully cloned by applying the RapMap method, and the RapMap is indicated to be a rapid and high-throughput gene cloning RapMap method integrating QTL positioning, verification and near-isogenic line screening into a whole.

The invention discloses a single-gene disease name recommendation method and system based on clinical features and sequence variations. The single-gene disease name recommendation method and system can accurately recommend single-gene disease names matched with the condition of a patient. The method comprises the following steps of acquiring case information of the patient; comparing a gene sequence with a human reference genome to obtain an influence score of each genetic variation; traversing a feature set A corresponding to each standard monogenic disease name in a feature relationship database, respectively calculating a set similarity value with each feature set A, outputting the similar standard monogenic disease names and corresponding gene descending order candidates, and constructing a standard monogenic disease name set P; obtaining a plurality of genes corresponding to the monogenic disease names from a preset gene list file, respectively calculating the pathogenicity scoreof each gene, outputting the corresponding standard monogenic disease name descending order candidates, and constructing a standard monogenic disease name set G; and outputting a recommendation resultof the standard monogenic disease names based on an intersection result of the set G and the set P.

Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy.

The invention discloses a method for identifying a cancer driver gene by using a consensus prediction result. The method comprises the following steps: S1, receiving a mutation annotation format (MAF) file as input; S2, processing all the preprocessed input mutation data so as to respectively obtain a candidate driver gene list of each strategy; S3, on the basis of each differential driving gene list, obtaining a common driving gene list by using a rank integration method RobustRankAggreg; S4, evaluating the performance of the result by using Top-N-Precision and Top-N-nDCG, and carrying out KEGG pathway and gene ontology analysis on the common driver gene; S5, obtaining a consensus driving gene list by using an RAA algorithm; S6, employing the SuperExactTest and the Circos for organizing a visualization result. The method has certain superiority in driver gene prediction, although height difference exists between different driver gene identification strategies, not only can the most reliable driver gene be identified through cross analysis of results of each independent strategy, but also potential novel driver genes with undefined features can be found.

There is described herein a method of prognosing endocrine-only treatment in a subject with breast cancer, the method comprising: a) providing a tumor sample of the breast cancer; b) determining the expression level of at least 40 of the genes listed in Table 4 in the tumor sample; c) comparing said expression levels to a reference expression level of the group of genes from control samples from acohort of subjects; and d) determining the residual risk associated with the breast cancer; wherein a statistically significant difference or similarity in the expression of the group of genes compared to the reference expression level corresponds to a residual risk associated with breast cancer.

This disclosure relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. In particular, this disclosure identifies epitopes that arose from disease-associated mutations, wherein the epitopes are predicted to elicit immune response from T cells. Specifically, this disclosure simultaneously considers peptide-level information, including MHC Class I and II presentation, helper and cytotoxic T cell response and sample-level information, including mutation clonality and MHC allele dosage. In some embodiment, the systems and methods are used for personalized treatment of cancers.